(R)-(-)-4,5,6,8,9,10-hexahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-pyrido-[3,2,1-jk]-carbazol-11-one hydrochloride monohydrate | 209859-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (R)-(-)-4,5,6,8,9,10-hexahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-11H-pyrido-[3,2,1-jk]-carbazol-11-one hydrochloride monohydrate
• 英文别名: cilansetron hydrochloride monohydrate；Cilansetron hydrochloride；(12R)-12-[(2-methylimidazol-1-yl)methyl]-1-azatetracyclo[7.6.1.05,16.010,15]hexadeca-5(16),6,8,10(15)-tetraen-11-one;hydrate;hydrochloride
• CAS: 209859-87-0
• 化学式: C₂₀H₂₁N₃O*ClH*H₂O
• 分子量: 373.882
• InChiKey: JXQUEAGLZNCBHC-QCUBGVIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  40.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• 4-hydroxy derivatives of 5,6,9,10-tetrahydro-10-((2-methyl-1h-imidazol-1-yl)methyl)-4h-pyrido-(3,2,1-jk)-carbazol-11(8h)-one
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1424337A1

  公开（公告）日：2004-06-02

  The present invention relates to novel 4-hydroxy derivatives of 5,6,9,10-tetrahydro-10-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-pyrido-[3,2,1-jk]-carbazol-11(8H)-one with 5-HT3-receptor antagonistic activity. Furthermore, the invention relates to a process for the preparation of the novel derivatives.

  本发明涉及具有5-HT3受体拮抗活性的新型5,6,9,10-四氢-10-[(2-甲基-1H-咪唑-1-基)甲基]-4H-吡啶并[3,2,1-jk]-咔唑-11(8H)-酮的4-羟基衍生物。此外，本发明还涉及一种制备这种新型衍生物的方法。
• Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
  申请人：——

  公开号：US20020040033A1

  公开（公告）日：2002-04-04

  The present invention relates to the use of cilansetron for the treatment of non-obstipative male IBS patients.

  本发明涉及使用西兰司琼治疗非便秘性男性肠易激综合征患者。
• Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
  申请人：Sann Holger

  公开号：US20050209293A1

  公开（公告）日：2005-09-22

  A method of treating or inhibiting non-digestive tract derived abdominal disorders associated with pain, in particular interstitial cystitis, chronic pelvic pain syndrome and/or abdominal pain associated with endometriosis, in a patient in need thereof, by administering to the patient a pharmaceutically effective amount of a 5-HT 3 receptor antagonist, in particular cilansetron, or a pharmacologically compatible derivative thereof, such as a salt and/or a solvates.

  一种治疗或抑制与疼痛相关的非消化道衍生腹部疾病，特别是间质性膀胱炎、慢性盆腔疼痛综合征和/或与子宫内膜异位症相关的腹痛的方法，该方法通过向有需要的患者施用药学有效量的 5-HT 3 受体拮抗剂，特别是西兰司琼，或其药理相容的衍生物，如盐和/或溶物。
• Process for the preparation of enantiomerically pure imidazolyl compounds
  申请人：DUPHAR INTERNATIONAL RESEARCH B.V

  公开号：EP0768309B1

  公开（公告）日：2002-09-25
• "Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron"
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP0895782B1

  公开（公告）日：2004-12-01